icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
2019 April 10-14
Vienna Austria
Back grey_arrow_rt.gif
 
 
 
PRO: Testing for HCV Resistance-Associated Variants (RAVs) in Patients After
DAA Failure and Impact on Subsequent Drug Selection

 
 
  EASL 2019
Vienna
Ira M. Jacobson, M.D.
Professor of Medicine
Director of Hepatology
NYU Langone Health
 
pdf of slide talk attached
 
this session had 3 talks, this PRO testing & then Jean Michel Pawlotsky the CON and a summary review afterwards by Christoph Sarrazin. Jules
 
WEBCAST: https://easl.meta-dcr.com/ilc2019/crs/pro-testing-for-hcv-resistance-associated-variants-ravs-in-patients-after-daa-failure-and-impact-on-subsequent-drug-selection

0426191

0426192

0426193

0426194

0426195

0426196

0426197

0426198

0426199

04261910

04261911

04261912

AASLD-SF 2018: High efficacy of glecaprevir/pibrentasvir in patients with chronic HCV GT1 infection who failed prior treatment with NS5A-inhibitor plus sofosbuvir regimens

04261913

04261914

04261915

04261916

04261917

04261918

04261919

04261920

04261921